Allan M. Skene
About
Allan M. Skene is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Economics and Econometrics.
According to data from OpenAlex, Allan M. Skene has authored 36 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cardiology and Cardiovascular Medicine, 9 papers in Surgery and 7 papers in Economics and Econometrics. Recurrent topics in Allan M. Skene's work include Acute Myocardial Infarction Research (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (6 papers). Allan M. Skene is often cited by papers focused on Acute Myocardial Infarction Research (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Atrial Fibrillation Management and Outcomes (6 papers). Allan M. Skene collaborates with scholars based in United Kingdom, United States and Canada. Allan M. Skene's co-authors include Carolyn H. McCabe, Eugene Braunwald, Christopher P. Cannon, Christopher P. Cannon, Marc A. Pfeffer, René Belder, Daniel J. Rader, Steven Joyal, Jean L. Rouleau and Robert F. Storey and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.
In The Last Decade
Allan M. Skene
35 papers receiving 13.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Allan M. Skene United Kingdom | 27 | 10.2k | 6.6k | 2.2k | 1.9k | 1.4k | 36 | 14.2k | ||
| Witold Rużyłło Poland | 39 | 10.0k 1.0× | 7.3k 1.1× | 1.4k 0.6× | 1.7k 0.9× | 1.2k 0.8× | 172 | 14.1k | ||
| José López‐Sendón Spain | 56 | 10.0k 1.0× | 4.1k 0.6× | 1.9k 0.9× | 1.2k 0.6× | 673 0.5× | 263 | 13.6k | ||
| Felicita Andreotti Italy | 45 | 10.1k 1.0× | 5.8k 0.9× | 1.9k 0.9× | 1.5k 0.8× | 626 0.5× | 179 | 15.2k | ||
| Shaun G. Goodman Canada | 70 | 14.8k 1.5× | 6.2k 0.9× | 1.6k 0.7× | 2.4k 1.3× | 1.3k 0.9× | 480 | 18.5k | ||
| R. Scott Wright United States | 48 | 8.7k 0.9× | 6.6k 1.0× | 2.0k 0.9× | 685 0.4× | 1.2k 0.9× | 122 | 15.0k | ||
| Harald Darius Germany | 43 | 11.8k 1.2× | 5.2k 0.8× | 1.4k 0.6× | 4.5k 2.4× | 1.6k 1.2× | 202 | 17.9k | ||
| Paul A. Gurbel United States | 63 | 14.1k 1.4× | 8.0k 1.2× | 1.7k 0.8× | 4.5k 2.4× | 426 0.3× | 419 | 17.7k | ||
| Robert M. Califf United States | 41 | 5.7k 0.6× | 6.9k 1.0× | 1.6k 0.7× | 453 0.2× | 1.7k 1.2× | 106 | 10.4k | ||
| Bariş Gencer Switzerland | 32 | 6.5k 0.6× | 3.7k 0.6× | 1.3k 0.6× | 685 0.4× | 659 0.5× | 188 | 9.9k | ||
| Shinya Goto Japan | 63 | 10.7k 1.1× | 4.2k 0.6× | 983 0.4× | 3.8k 2.0× | 713 0.5× | 293 | 15.2k |
Countries citing papers authored by Allan M. Skene
Since
Specialization
Citations
This map shows the geographic impact of Allan M. Skene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan M. Skene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan M. Skene more than expected).
Fields of papers citing papers by Allan M. Skene
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Allan M. Skene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan M. Skene. The network helps show where Allan M. Skene may publish in the future.
Co-authorship network of co-authors of Allan M. Skene
This figure shows the co-authorship network connecting the top 25 collaborators of Allan M. Skene. A scholar is included among the top collaborators of Allan M. Skene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan M. Skene. Allan M. Skene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wallentin, Lars, Richard C. Becker, Andrzej Budaj, et al.. (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 361(11). 1045–1057.
2.
James, Stefan, Axel Åkerblom, Christopher P. Cannon, et al.. (2009). Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal. 157(4). 599–605.
3.
Erdmann, Erland, John Dormandy, B Charbonnel, et al.. (2007). The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction. Journal of the American College of Cardiology. 49(17). 1772–1780.
4.
Morrow, David A., Benjamin M. Scirica, Ewa Karwatowska‐Prokopczuk, et al.. (2006). Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. American Heart Journal. 151(6). 1186.e1–1186.e9.
5.
Scirica, Benjamin M., Christopher P. Cannon, Richard A. Cooper, et al.. (2006). Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. Journal of Thrombosis and Thrombolysis. 22(2). 95–102.
6.
Ray, Kausik K., Christopher P. Cannon, Richard Cairns, et al.. (2005). Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology. 46(8). 1417–1424.
7.
Torp‐Pedersen, Christian, Philip A. Poole‐Wilson, Karl Swedberg, et al.. (2005). Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. American Heart Journal. 149(2). 370–376.
8.
Sabatine, Marc S., Christopher P. Cannon, C. Michael Gibson, et al.. (2005). Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine. 352(12). 1179–1189.
9.
Cannon, Christopher P., Eugene Braunwald, Carolyn H. McCabe, et al.. (2004). Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms. Obstetrical & Gynecological Survey. 59(7). 522–524.
10.
Charbonnel, B, et al.. (2004). The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). Diabetes Care. 27(7). 1647–1653.
11.
Cannon, Christopher P., Eugene Braunwald, Carolyn H. McCabe, et al.. (2004). Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 350(15). 1495–1504.
12.
Poole‐Wilson, Philip A., Karl Swedberg, John G.F. Cleland, et al.. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet. 362(9377). 7–13.
13.
O’Shea, J.Conor, Robert G. Wilcox, Allan M. Skene, et al.. (2002). Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. The American Journal of Cardiology. 90(12). 1374–1377.
14.
Brown, Nigel, M Melville, Denis Pereira Gray, et al.. (2000). Comparison of the SF-36 health survey questionnaire with the Nottingham health profile in long-term survivors of a myocardial infarction. Journal of Public Health. 22(2). 167–175.
15.
Skene, Allan M., et al.. (2000). Graft material and results of platelet inhibitor trials in peripheral arterial reconstructions: reappraisal of results from a meta‐analysis. British Journal of Clinical Pharmacology. 49(5). 479–483.
16.
Brown, Nigel, Tracey Young, David Gray, Allan M. Skene, & J R Hampton. (1997). Inpatient deaths from acute myocardial infarction, 1982-92: analysis of data in the Nottingham heart attack register. BMJ. 315(7101). 159–164.
17.
Skene, Allan M., et al.. (1993). The use of simulation in the design of two cardiovascular survival studies. Statistics in Medicine. 12(12). 1365–1372.
18.
Skene, Allan M., et al.. (1992). Sample sizes for proportional hazards survival studies with arbitrary patient entry and loss to follow‐up distributions. Statistics in Medicine. 11(8). 1103–1113.
19.
Wilcox, Robert G., Carl Olsson, Allan M. Skene, et al.. (1988). TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION. The Lancet. 332(8610). 525–530.
20.
Reeves, W G, David P. Barr, K. Gelsthorpe, et al.. (1984). Factors governing the human immune response to injected insulin. Diabetologia. 26(4). 266–71.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Witold Rużyłło Breakdown of academic impact, for papers by José López‐Sendón Breakdown of academic impact, for papers by Felicita Andreotti Breakdown of academic impact, for papers by Shaun G. Goodman Breakdown of academic impact, for papers by R. Scott Wright Breakdown of academic impact, for papers by Harald Darius Breakdown of academic impact, for papers by Paul A. Gurbel Breakdown of academic impact, for papers by Robert M. Califf Breakdown of academic impact, for papers by Bariş Gencer Breakdown of academic impact, for papers by Shinya Goto